Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NinePoint makes ex-NeuroTherm chief CEO

This article was originally published in Clinica

Executive Summary

Organ imaging specialist NinePoint Medical has appointed Christopher von Jako president and CEO. He replaces Charles Carignan, who in July left to head up personal bionics company BiOM. Dr von Jako previously led spinal pain treatment firm NeuroTherm, which was acquired by St Jude Medical for $200m in July. Before this, he was president of minimally-invasive navigation solutions developer ActiViews, and has also worked for Integra LifeSciences, Covidien, Medtronic and Radionics. Cambridge, Massachusetts-based NinePoint has developed the NvisionVLE Imaging System that enables physicians to endoscopically view the esophagus; the information can be used for biopsy or treatment planning. The system was first FDA 510(k)-cleared in 2012, and it is also CE marked in Europe. In March, Ninepoint completed a $34m series B financing, which will support the ongoing launch of NvisionVLE in the US.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT102166

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel